Azzolini 2016 Abstract Mito Xmas Meeting Innsbruck: Difference between revisions
Beno Marija (talk | contribs) (Created page with "{{Abstract |title= |authors= |year=2016 |event=Mito Xmas Meeting 2016 Innsbruck AT |abstract= }} {{Labeling }} == Affiliations == :::: ::::#") Β |
Beno Marija (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{Abstract | {{Abstract | ||
|title= | |title=Targeting a mitochondrial potassium channel as a newΒ to treat Chronic Lymphocytic Leukemia. | ||
|authors= | Β | ||
|authors=Azzolini M, Martini V, Severin F, Romio M, Mattarei A, Zoratti M, Trentin L, Semenzato G, Paradisi C, Leanza L, SzabΓ² I | |||
|year=2016 | |year=2016 | ||
|event=Mito Xmas Meeting 2016 Innsbruck AT | |event=Mito Xmas Meeting 2016 Innsbruck AT | ||
|abstract= | |abstract=Human Chronic Lymphocytic Leukemia (B-CLL) is the most commonly diagnosed leukemia in the Western World. Therapeutic options to treat this leukemia are very limited. B-CLL is characterized by a clonal accumulation of mature neoplastic B cells that are resistant to apoptosis. Different leukemic cells or cell lines, both myeloid and lymphoid, express/overexpress several potassium channels including shaker type voltage-gated Kv1.3, Kv11.1 (Herg), and calcium-activated KCa3.1, and their pharmacological inhibition has been related to reduced B-CLL proliferation, pointing to ion channels as promising oncological targets in B-CLL. We obtained evidence that Kv1.3 is highly expressed in B-CLL respect to normal B cells both in the plasma membrane and in the inner mitochondrial membrane. We have recently shown that the treatment with mitochondrial Kv1.3 inhibitors actively killed primary B-CLL cells in ex-vivo experiments, by induction of intrinsic apoptosis. Importantly, cells form healthy subjects and even residual normal T lymphocytes of the same patients were unaffected by the drugs, while B-CLL cells were killed. Importantly, B-CLL cell death was observed also when leukemic cells were co-cultured with mesenchymal stromal cells (MSC), which favor tumor cell growth by releasing anti-apoptotic and pro-survival factors. Here we report the first in vivo evidence, that pharmacological targeting of the mitochondrial Kv1.3 by a new mitochondrial targeted inhibitor is sufficient to lead to a massive CD5+/CD19+ elimination in several organs (blood, peritoneal cavity, spleen, bone marrow) in a B-CLL genetic mouse model (EuTCL-1), without inducing side effects and death in healthy immune cells, including cytotoxic T lymphocytes. These results open the possibility to a new therapeutical approach for this disease by directly targeting the mitochondrial channel. | ||
Β | |||
Β | |||
|mipnetlab=RU Moscow Skulachev VP | |||
}} | }} | ||
{{Labeling | {{Labeling | ||
|event=Poster | |||
}} | }} | ||
== Affiliations == | == Affiliations == | ||
:::: Β | :::: Azzolini M(1,2), Martini V(3), Severin F(3), Romio M(4), Mattarei A(4), Zoratti M(1,2), Trentin L(3), Semenzato G(3), Paradisi C(4), Leanza L(5), SzabΓ² I(1,5) | ||
::::# | ::::# CNR Inst Neurosciences, Padua, Italy | ||
::::# Dept Biomedical Sc, Univ Padua, Italy | |||
::::# Dept Chemical Sc, Univ Padua, Italy | |||
::::# Dept Medicine, Hematology Immunological Branch, Univ Padova, Venetian Inst for Molecular Medicine (VIMM), via G. Orus 2, I-35129 Padova, Italy | |||
::::# Dept Biology, Univ Padua, Italy |
Revision as of 12:26, 7 December 2016
Targeting a mitochondrial potassium channel as a new to treat Chronic Lymphocytic Leukemia. |
Link:
Azzolini M, Martini V, Severin F, Romio M, Mattarei A, Zoratti M, Trentin L, Semenzato G, Paradisi C, Leanza L, SzabΓ² I (2016)
Event: Mito Xmas Meeting 2016 Innsbruck AT
Human Chronic Lymphocytic Leukemia (B-CLL) is the most commonly diagnosed leukemia in the Western World. Therapeutic options to treat this leukemia are very limited. B-CLL is characterized by a clonal accumulation of mature neoplastic B cells that are resistant to apoptosis. Different leukemic cells or cell lines, both myeloid and lymphoid, express/overexpress several potassium channels including shaker type voltage-gated Kv1.3, Kv11.1 (Herg), and calcium-activated KCa3.1, and their pharmacological inhibition has been related to reduced B-CLL proliferation, pointing to ion channels as promising oncological targets in B-CLL. We obtained evidence that Kv1.3 is highly expressed in B-CLL respect to normal B cells both in the plasma membrane and in the inner mitochondrial membrane. We have recently shown that the treatment with mitochondrial Kv1.3 inhibitors actively killed primary B-CLL cells in ex-vivo experiments, by induction of intrinsic apoptosis. Importantly, cells form healthy subjects and even residual normal T lymphocytes of the same patients were unaffected by the drugs, while B-CLL cells were killed. Importantly, B-CLL cell death was observed also when leukemic cells were co-cultured with mesenchymal stromal cells (MSC), which favor tumor cell growth by releasing anti-apoptotic and pro-survival factors. Here we report the first in vivo evidence, that pharmacological targeting of the mitochondrial Kv1.3 by a new mitochondrial targeted inhibitor is sufficient to lead to a massive CD5+/CD19+ elimination in several organs (blood, peritoneal cavity, spleen, bone marrow) in a B-CLL genetic mouse model (EuTCL-1), without inducing side effects and death in healthy immune cells, including cytotoxic T lymphocytes. These results open the possibility to a new therapeutical approach for this disease by directly targeting the mitochondrial channel.
β’ O2k-Network Lab: RU Moscow Skulachev VP
Labels:
Event: Poster
Affiliations
- Azzolini M(1,2), Martini V(3), Severin F(3), Romio M(4), Mattarei A(4), Zoratti M(1,2), Trentin L(3), Semenzato G(3), Paradisi C(4), Leanza L(5), SzabΓ² I(1,5)
- CNR Inst Neurosciences, Padua, Italy
- Dept Biomedical Sc, Univ Padua, Italy
- Dept Chemical Sc, Univ Padua, Italy
- Dept Medicine, Hematology Immunological Branch, Univ Padova, Venetian Inst for Molecular Medicine (VIMM), via G. Orus 2, I-35129 Padova, Italy
- Dept Biology, Univ Padua, Italy